DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The "Muscarinic Acetylcholine Receptor M2 Antagonist -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

'Muscarinic Acetylcholine Receptor M2 Antagonist - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Muscarinic Acetylcholine Receptor M2 Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

ClinicalNon-clinicalInactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Muscarinic Acetylcholine Receptor M2 Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Muscarinic Acetylcholine Receptor M2 Antagonist pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report:

Provides a snapshot of the therapeutics pipeline activity for Muscarinic Acetylcholine Receptor M2 AntagonistFeatures the Muscarinic Acetylcholine Receptor M2 Antagonist pipeline across the complete product development cycle including all clinical and non-clinical stagesOffers detailed therapeutic product profiles of Muscarinic Acetylcholine Receptor M2 Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical informationTherapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administrationCoverage of dormant and discontinued pipeline projects across Muscarinic Acetylcholine Receptor M2 Antagonist

Key Topics Covered:

1. Report Introduction

2. Muscarinic Acetylcholine Receptor M2 Antagonist - Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Muscarinic Acetylcholine Receptor M2 Antagonist

4. Comparative Analysis

5. Muscarinic Acetylcholine Receptor M2 Antagonist Pipeline Products in Clinical Stages

Product DescriptionResearch and DevelopmentProduct Development Activities

Other product profiles in the detailed report..

6. Muscarinic Acetylcholine Receptor M2 Antagonist Pipeline Products in Non-clinical Stages

Product DescriptionResearch and DevelopmentProduct Development Activities

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of AdministrationPipeline Assessment by Stage and Route of AdministrationPipeline Assessment by Molecule TypePipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

Product DescriptionResearch and DevelopmentProduct Development ActivitiesReason for dormancy/discontinuation

Companies Mentioned

Astellas PharmaZeriaAnavex Life Sciences

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/dnb2jq/muscarinic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005412/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/30/2018 12:50 PM/DISC: 11/30/2018 12:50 PM

http://www.businesswire.com/news/home/20181130005412/en

Copyright Business Wire 2018.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.